{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Muhammad N"],"funding":["Fundamental Research Funds for the Central Universities","Shanxi Provincial Key Research and Development Project","National Natural Science Foundation of China"],"pagination":["729-741"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8908045"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24"],"pubmed_abstract":["Chimeric antigen receptor T cell (CAR-T) therapy has been shown to be an effective strategy for combatting non-solid tumors; however, CAR-T therapy is still a challenge for solid tumors, such as glioblastoma. To improve CAR-T therapy for glioblastoma, a new TanCAR, comprising the tandem arrangement of IL13 (4MS) and EphA2 scFv, was generated and validated <i>in vitro</i> and <i>in vivo. In vitro</i>, the novel TanCAR-redirected T cells killed glioblastoma tumor cells by recognizing either IL-13 receptor α2 (IL13Rα2) or EphA2 alone or together upon simultaneous encounter of both targets, but did not kill normal cells bearing only the IL13Rα1/IL4Rα receptor. As further proof of principle, the novel TanCAR was tested in a subcutaneous glioma xenograft mouse model. The results indicated that t"],"journal":["Molecular therapy oncolytics"],"pubmed_title":["A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy."],"pmcid":["PMC8908045"],"funding_grant_id":["GK202107018","2018SF-106","81773265","SY20210003"],"pubmed_authors":["Muhammad N","Li W","Xia H","Zheng X","Hu Y","Wang R","Zhang Z","Mao Q","Chang Y","Zhao J"],"additional_accession":[]},"is_claimable":false,"name":"A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy.","description":"Chimeric antigen receptor T cell (CAR-T) therapy has been shown to be an effective strategy for combatting non-solid tumors; however, CAR-T therapy is still a challenge for solid tumors, such as glioblastoma. To improve CAR-T therapy for glioblastoma, a new TanCAR, comprising the tandem arrangement of IL13 (4MS) and EphA2 scFv, was generated and validated <i>in vitro</i> and <i>in vivo. In vitro</i>, the novel TanCAR-redirected T cells killed glioblastoma tumor cells by recognizing either IL-13 receptor α2 (IL13Rα2) or EphA2 alone or together upon simultaneous encounter of both targets, but did not kill normal cells bearing only the IL13Rα1/IL4Rα receptor. As further proof of principle, the novel TanCAR was tested in a subcutaneous glioma xenograft mouse model. The results indicated that t","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-19T09:25:27.981Z","creation":"2025-04-19T09:25:27.981Z"},"accession":"S-EPMC8908045","cross_references":{"pubmed":["35317513"],"doi":["10.1016/j.omto.2022.02.012"]}}